Petra Pharma is developing small-molecule inhibitors targeting enzyme pathways implicated in cancer and metabolic diseases, operating under a multiyear research alliance with Weill Cornell Medicine, which is a stakeholder. The company was co-founded by Lewis Cantley and Nathanael Gray, both noted researchers in cancer biology and kinase inhibitor discovery. Petra’s scientific approach focuses on interrogating novel enzyme targets involved in cell division, growth, trafficking and signaling to create next-generation therapies. Accelerator Corporation will oversee Petra’s early operations under its investment and management model, providing business management and scientific oversight. The company plans to concentrate on achieving key value-building scientific milestones to translate discoveries into clinical candidates. Petra’s offices and labs will be located within Accelerator’s facilities at the Alexandria Center for Life Science in New York City.

Total raised

$48M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2016